159 related articles for article (PubMed ID: 30013444)
1. The Combination Of Weak Expression Of PRDX4 And Very High MIB-1 Labelling Index Independently Predicts Shorter Disease-free Survival In Stage I Lung Adenocarcinoma.
Shioya A; Guo X; Motono N; Mizuguchi S; Kurose N; Nakada S; Aikawa A; Ikeda Y; Uramoto H; Yamada S
Int J Med Sci; 2018; 15(10):1025-1034. PubMed ID: 30013444
[No Abstract] [Full Text] [Related]
2. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
3. The combination of strong expression of ZNF143 and high MIB-1 labelling index independently predicts shorter disease-specific survival in lung adenocarcinoma.
Kawatsu Y; Kitada S; Uramoto H; Zhi L; Takeda T; Kimura T; Horie S; Tanaka F; Sasaguri Y; Izumi H; Kohno K; Yamada S
Br J Cancer; 2014 May; 110(10):2583-92. PubMed ID: 24736586
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
[TBL] [Abstract][Full Text] [Related]
5. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
6. The combination of the low immunohistochemical expression of peroxiredoxin 4 and perilipin 2 predicts longer survival in pancreatic ductal adenocarcinoma with peroxiredoxin 4 possibly playing a main role.
Han J; Itoh T; Shioya A; Sakurai M; Oyama T; Kumagai M; Takamura H; Okuro M; Mukai T; Kitakata H; Inagaki M; Higashi M; Guo X; Yamada S
Histol Histopathol; 2023 Dec; 38(12):1415-1427. PubMed ID: 37787446
[TBL] [Abstract][Full Text] [Related]
7. Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y; Fan Q; Guo Y; Zhu K
Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
[TBL] [Abstract][Full Text] [Related]
8. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
[TBL] [Abstract][Full Text] [Related]
9. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma.
Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ
Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818
[No Abstract] [Full Text] [Related]
11. A Recurrence-Specific Gene-Based Prognosis Prediction Model for Lung Adenocarcinoma through Machine Learning Algorithm.
Xu S; Zhou J; Liu K; Chen Z; He Z
Biomed Res Int; 2020; 2020():9124792. PubMed ID: 33224985
[TBL] [Abstract][Full Text] [Related]
12. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
13. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
Liu X; Chen L; Zhang T
Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
[TBL] [Abstract][Full Text] [Related]
14. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
15. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
Zhong M; Jiang Q; Jin R
IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299
[TBL] [Abstract][Full Text] [Related]
16. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
17. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PELP1 in Lung Adenocarcinoma Promoted E
Zhang D; Dai J; Pan Y; Wang X; Qiao J; Sasano H; Zhao B; McNamara KM; Guan X; Liu L; Zhang Y; Chan MSM; Cao S; Liu M; Song S; Wang L
Pathol Oncol Res; 2021; 27():582443. PubMed ID: 34257530
[TBL] [Abstract][Full Text] [Related]
19. LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma.
Hou XM; Yuan SQ; Zhao D; Liu XJ; Wu XA
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509961
[TBL] [Abstract][Full Text] [Related]
20. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
